Daiichi Sankyo
Meng Pan possesses extensive experience in statistical programming, currently serving as Senior Director at Daiichi Sankyo US since October 2018, with prior roles including Director and Associate Director at the same company. Previously, Meng Pan held the position of Associate Director in Statistical Programming at Acceleron Pharma for a brief period in 2018, and served as Senior Manager in Statistical Programming at Eli Lilly and Company from September 2009 to March 2018. Educationally, Meng Pan holds a Master of Science degree in Chemistry from the University of Chicago and a Master of Science in Biostatistics from Rutgers University.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.